ãã€ãªå»è¬åäŒç€Ÿã§ãã Axsome Therapeutics, Inc. ã¯ãç±³åœã§äžæ¢ç¥çµç³» (CNS) é害ã«å¯Ÿããæ°ããæ²»çæ³ã®éçºã«åãçµãã§ããŸããå瀟ã®è£œåãã€ãã©ã€ã³ã«ã¯ã倧ãã€ç
æ§é害ããã³é£æ²»æ§ãã€ç
ã®æ²»çè¬ AXS-05 ãå«ãŸããŠããŸããããã¯ã¢ã«ããã€ããŒç
ã®èå¥®ã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšäžã§ãããçŠç
æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšãå®äºããŠããŸããå瀟ã¯ãŸããçé çæ²»çè¬ AXS-07ããã«ã³ã¬ãã·ãŒæ²»çè¬ AXS-12ãç·ç¶çççæ²»çè¬ AXS-14 ãéçºäžã§ããAxsome Therapeutics, Inc. ã¯ãçŠç
ã«ããã AXS-05 ã®è©äŸ¡ã«ã€ããŠãã¥ãŒã¯å€§åŠãšå
±åç ç©¶å¥çŽãçµãã§ããŸããå瀟㯠2012 幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ ç¹ã眮ããŠããŸãã